|The full article is available to subscribers||Subscriber Login|
The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab (Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of or whose disease was unresponsive to treatment with immunomodulators or corticosteroids, or a tumor necrosis factor (TNF) inhibitor. Ustekinumab was approved earlier for treatment of psoriasis and psoriatic arthritis.1,2
STANDARD TREATMENT — Corticosteroids are used to induce remission of Crohn's disease. Azathioprine or 6-mercaptopurine (6-MP) can be used for maintenance of remission. A TNF inhibitor alone or in combination with azathioprine or 6-MP can be used for both induction and maintenance of remission in patients with moderate to severe disease.3 The integrin receptor antagonist vedolizumab (Entyvio) can be used... more
- Drugs for psoriasis. Med Lett Drugs Ther 2015; 57:81.
- Drugs for psoriatic arthritis. Med Lett Drugs Ther 2015; 57:e88.
- Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2014; 56:65.
- Vedolizumab (Entyvio) for inflammatory bowel disease. Med Lett Drugs Ther 2014; 56:86.
- W Strober et al. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol 2010; 26:310.
- B Feagan et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016; 375:1946.
- KA Papp et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168:844.